Truelinked Biotech-B (02509) has repurchased a total of 3.4292 million shares according to the repurchase authorization.

The Chanto Finance APP News, Shunson Biomedical-B (02509) announced that the board of directors of the company believes that the current stock price of the company significantly undervalues the company's worth. With full confidence in the future development prospects of the company and a high recognition of the company's intrinsic value, in order to continuously enhance market confidence in the company and increase the investment value of the company, in accordance with the share repurchase authorization granted to the directors of the company by the shareholders at the annual general meetings held on June 20, 2025 and May 29, 2026, the company has repurchased a total of 3.4292 million ordinary shares as treasury shares from the Hong Kong Stock Exchange from November 6, 2025, to the date of this announcement. The repurchased shares account for approximately 1.51% of the company's total issued share capital as of the date of this announcement. The total amount involved in the repurchase as of the date of this announcement is approximately HK$65.66 million (excluding commissions and other expenses).